Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration

Journal of Infection and Chemotherapy

Volumn 12, Issue 1, 2006, Pages 1-8

  Fukuda, Yoshiko ^a   Takahata, Masahiro ^a   Mitsuyama, Junichi ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Pharmacokinetics; Simulation; Streptococcus pneumoniae; Tosufloxacin

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOSUFLOXACIN TOSILATE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SCREENING; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SIMULATION; STREPTOCOCCUS PNEUMONIA;

EID: 33644602152     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-005-0420-0     Document Type: Article

References (35)

1. P Ball 1999 Therapy for pneumococcal infection at the millennium: doubts and certainties Am J Med 107 77S 85S
2. JM Blondeau A Xilin G Hansen K Drlica 2001 Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 433 8
3. X Pan J Ambler S Mehtar LM Fisher 1996 Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae Antimicrob Agents Chemother 40 2321 6
4. J Tankovic B Perichon J Duval P Courvalin 1996 Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro Antimicrob Agents Chemother 40 2505 10
5. D Hoban K Waites D Felmingham 2003 Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study Diagn Microbiol Infect Dis 45 251 9
6. M Inoue S Kohno M Kaku K Yamaguchi J Igari K Yamanaka 2005 PROTEKT 1999-2000: a multicentre study of the antimicrobial susceptibility of respiratory tract pathogens in Japan Int J Infect Dis 9 27 36
7. D Bast DE Low CL Duncan L Kilburn LA Mandell RJ Davidson 2000 Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance Antimicrob Agents Chemother 44 3049 54
8. JM Blondeau 1999 A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones J Antimicrob Chemother 43 suppl B 1S 11S
9. K Bush R Goldschmidt 2000 Effectiveness of fluoroquinolones against gram-positive bacteria Curr Opin Invest Drugs 1 22 30
10. GG Zhanel K Ennis L Vercaigne AS Gin J Embil DJ Hoban 2002 Critical review of fluoroquinolones: focus on respiratory infections Drugs 62 13 59
11. PL Ho RW Yung DN Tsang TL Que M Ho WH Seto 2001 Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000 J Antimicrob Chemother 48 659 65
12. R Canton M Morosini MC Enright I Morrissey 2003 Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme J Antimicrob Chemother 52 944 52
13. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. Tokyo: The Japanese Respiratory Society; 2000. p. 31-9
14. K Yamaguchi S Miyazaki F Kashitani M Iwata M Kanda Y Tsujio 2000 Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin-Surveillance Group Jpn J Antibiot 53 387 408
15. J Mitsuyama 1999 Structure of existing and new quinolones and relationship to bactericidal activity against Streptococcus pneumoniae J Antimicrob Chemother 44 201 7
16. M Nakashima T Uematsu M Kanamaru T Yasuda Y Watanabe M Tai 1988 Phase I study of T-3262, a new pyridonecarboxylic acid derivative Chemotherapy 36 158 80
17. M Nakashima T Uematsu K Kosuge H Kusajima T Ooie H Uchida 1992 Phase I study of levofloxacin, (S)-(-)-ofloxacin Jpn J Clin Pharmacol Ther 23 515 20
18. M Maekawa Y Fukuda Y Sugiura T Kamiyama N Futakuchi M Takahata 2003 Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae Jpn J Antibiot 56 27 3
19. MN Dudley 1991 Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones Am J Med 91 45S 50S
20. JT Smith 1984 Awakening the slumbering potential of the 4-quinolone antibacterials Pharm J 233 299 305
21. A Forrest DE Nix CH Ballow TF Goss MC Birmingham JJ Schentag 1993 Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 1073 81
22. SL Preston GL Drusano AL Berman CL Fowler AT Chow B Dornsief 1998 Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials JAMA 273 125 9
23. MK Lacey W Lu X Xu PR Tessier DP Nicolau R Quintilliani 1999 Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro pharmacokinetic model Antimicrob Agents Chemother 43 672 7
24. PD Lister CC Sanderes 1999 Pharmacodynamics of trovafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model Antimicrob Agents Chemother 43 1118 23
25. PD Lister 2002 Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication Antimicrob Agents Chemother 46 69 74
26. E Hershberger MJ Rybak 2000 Activities of trovafloxacin, clinafloxacin, sparfloxacin, levofloxacin and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae Antimicrob Agents Chemother 44 598 601
27. CG Zhanel D Roberts A Waltky N Laing K Nichol DJ Hoban 2002 Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae J Antimicrob Chemother 49 807 12
28. A Tsuji T Sugano K Yamaguchi S Goto T Takada Y Takase 1994 Evaluation of bactericidal activity of arbekacin in mixed culture with MRSA and Pseudomonas aeruginosa using an in vitro pharmacokinetic simulation system Jpn J Antibiot 47 655 63
29. KJ Madaras-Kelly TA Demasters 2000 In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae Diagn Microbial Infect Dis 37 253 60
30. ME Kleoser EJ Ernst CR Petzold P Rhomberg GV Doern 2001 Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model Antimicrob Agents Chemother 45 673 8
31. H Ebisu R Kishi M Takei H Fukuda 2003 The effect of pharmacokinetic/ pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolate of Streptococcus pneumoniae J Infect Chemother 9 210 4
32. M Tanaka Y Uchida K Yoshida T Akasaka Y Murakami K Sato 2000 Bactericidal activity of levofloxacin in in-vitro simulation system model Jpn J Chemother 48 325 32
33. The Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS). Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement. 2004;M100-S14 24(1):120-2
34. TA Davies A Evangelista S Pfleger K Bush DF Sahm R Goldschmidt 2002 Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae isolated in the United States in 1992-1996 and 1999-2000 Antimicrob Agents Chemother 46 119 24
35. AB Brueggemann SL Coffman P Rhomberg H Huynh L Almer A Nilius R Flamm GV Doern 2002 Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995 Antimicrob Agents Chemother 46 680 88